Processa Pharmaceuticals, Inc. has amended its previous SEC filing to provide updated financial information regarding its recent acquisition of Vidya Therapeutics, Inc. This amendment, filed on October 5, 2026, is significant as it enhances the transparency of Processa's financial standing following the acquisition.
The filing clarifies that the amendment includes audited financial statements of Vidya for the years ended December 31, 2025, and 2024, as well as unaudited interim financial statements for the first half of 2026. This information is crucial for investors and stakeholders as it sheds light on the financial performance of the acquired entity.
Background
Processa Pharmaceuticals, Inc. operates in the pharmaceutical preparations industry (SIC 2834) and is listed on the Nasdaq under the ticker symbol PCSA. The company is incorporated in Delaware and is classified as an emerging growth company. Recent filings include a 10-Q on August 14, 2026, and a DEF 14A on October 22, 2026.
What the Filing Says
The amended filing states, "This Amendment No. 1 is filed to update the information in Item 9.01(a) of the Original Report to include the audited financial statements of Vidya as of and for the years ended December 31, 2025 and 2024 and the unaudited interim condensed consolidated financial statements of Vidya as of and for the six months ended June 30, 2026 and 2025." Additionally, it includes pro forma financial information for Processa as of June 30, 2026.
Impact
This filing may affect investors and stakeholders of Processa Pharmaceuticals by providing a clearer picture of the company's financial health post-acquisition. It also sets a precedent for other companies in the pharmaceutical preparations sector, potentially influencing their acquisition strategies and reporting practices.
What's Next
The filing does not say what happens next regarding further actions or filings related to this acquisition.